Contact
Score Calculators

Biomarker discovery

Ongoing research

A possible role for FXR polymorphisms in the etiopathogenesis of acute decompensation of cirrhosis and ACLF: An observational study within CANONIC and PREDICT

Biomarkers of renal tubular damage in predicting response to terlipressin and albumin in patients with hepatorenal syndrome

CHANCE: Liver transplantation in patients with cirrhosis and severe acute-on-chronic liver failure – Indications and outcomes

DECISION: Decompensated cirrhosis – Identification of new combinatorial therapies based on systems approaches

Extracellular vesicles as biomarkers in patients with acute decompensation of cirrhosis

Glycomics-based biomarkers for diagnosis and prognosis in ACLF

Identification of albumin receptors and characterization of albumin intracellular trafficking in human peripheral blood mononuclear cells

MICROB-PREDICT: Microbiome-based biomarkers to predict decompensation of liver cirrhosis and treatment response

Molecular markers to predict chronic liver failure and to explore its mechanistic pathways in decompensated cirrhosis

Meet the principal investigators working on biomarker discovery

Paolo Angeli

MD, PhD

William Bernal

MD

Cornelius Engelmann

MD, PhD

Javier Fernández

MD, PhD

Thierry Gustot

MD, PhD

Rajiv Jalan

MD, PhD

Wim Laleman

MD, PhD

Salvatore Piano

MD, PhD

Pierre-Emmanuel Rautou

MD, PhD

Loredana Saveanu

MD, PhD

Jonel Trebicka

MD, PhD

Xavier Verhelst

MD, PhD

Related News

Findings from the CHANCE study urge the need for improved graft allocation policies

20 June 2024

Findings from the CHANCE study urge the need for improved graft allocation policies
Interim results from the CHANCE study presented at ELITA Summit 2024

20 April 2024

Interim results from the CHANCE study presented at ELITA Summit 2024
CHANCE study enters phase 2 to define liver transplantation futility criteria in patients with severe ACLF

1 February 2024

CHANCE study enters phase 2 to define liver transplantation futility criteria in patients with severe ACLF
The 5th DECISION General Assembly highlights the commitment and collaborative effort of all partners in the Consortium

20 October 2023

The 5th DECISION General Assembly highlights the commitment and collaborative effort of all partners in the Consortium
View all news

Registered office

European Foundation for the Study of
Chronic Liver Failure
Travessera de Gràcia 11, 7th floor
08021 Barcelona, Spain

Legal

Contact us

T +34 93 227 14 00
E efclif@efclif.com

© European Foundation for the Study of Chronic Liver Failure 2024